Public perspectives on disinvestments in drug funding: results from a Canadian deliberative public engagement event on cancer drugs

BACKGROUND: Decisions relating to the funding of new drugs are becoming increasingly challenging due to a combination of aging populations, rapidly increasing list prices, and greater numbers of drug-indication pairs being brought to market. This is especially true in cancer, where rapid list price...

Descripción completa

Detalles Bibliográficos
Autores principales: Costa, Sarah, Bentley, Colene, Regier, Dean A., McTaggart-Cowan, Helen, Mitton, Craig, Burgess, Michael M., Peacock, Stuart J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647147/
https://www.ncbi.nlm.nih.gov/pubmed/31331312
http://dx.doi.org/10.1186/s12889-019-7303-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647147/
https://www.ncbi.nlm.nih.gov/pubmed/31331312
http://dx.doi.org/10.1186/s12889-019-7303-2

Ejemplares similares